Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Not Applicable

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Drug: busulfan
Radiation: total-body irradiation
Drug: carboplatin
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: carmustine
Drug: thiotepa
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-09-28

Last Posted Date: 2021-04-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 174

Registration Number: NCT00536601

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: ARA-C
Drug: BCNU
Drug: Campath-1H
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine
Drug: Melphalan
Drug: Rituximab
Other: Allogeneic Stem Cell Transplantation
Radiation: Total body radiation (TBI)
Drug: Methotrexate
Drug: Tacrolimus
Procedure: Adback NK or T Cell

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00536978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Leukemia

Interventions: Drug: busulfan
Drug: cyclosporine
Drug: etoposide
Drug: mycophenolate mofetil
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-09-24

Last Posted Date: 2024-02-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 30

Registration Number: NCT00534430

Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Biological: aldesleukin
Biological: filgrastim
Drug: busulfan
Drug: cytarabine
Drug: etoposide
Drug: idarubicin
Procedure: autologous hematopoietic stem cell transplantation
Procedure: bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2007-09-24

Last Posted Date: 2024-04-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 60

Registration Number: NCT00534469

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: SGN-40
Drug: placebo
Drug: rituximab
Drug: etoposide
Drug: carboplatin
Drug: ifosfamide

First Posted Date: 2007-09-14

Last Posted Date: 2015-02-25

Lead Sponsor: Seagen Inc.

Target Recruit Count: 151

Registration Number: NCT00529503

Locations: 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇦🇺
St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia

and more 63 locations

LAL-BR/2001: Study Treatment to Low Risk ALL

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2016-01-20

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 150

Registration Number: NCT00526175

Locations: 🇪🇸
Basurtuko Ospitalea, Basurto, Spain
🇪🇸
Complejo Hospitalario Universitario de Albacete, Albacete, Spain
🇪🇸
Hospital General de Alicante, Alicante, Spain

and more 22 locations

STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: cisplatin
Drug: etoposide

First Posted Date: 2007-09-10

Last Posted Date: 2023-03-24

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 160

Registration Number: NCT00526396

Locations: 🇮🇹
Ospedale E. Morelli, Sondalo, SO, Italy
🇮🇹
Istituto Nazionale dei Tumori, Napoli, Italy
🇮🇹
Ospedale L. Sacco Polo Universitario, Milano, Italy

and more 9 locations

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Biological: sargramostim
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-08-27

Last Posted Date: 2015-12-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT00521014

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2007-08-10

Last Posted Date: 2020-09-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 121

Registration Number: NCT00514540

Locations: 🇺🇸
University of California-San Francisco, San Francisco, California, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporin-A
Drug: etoposide
Drug: methotrexate
Drug: rasburicase
Drug: sirolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: tacrolimus
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: fludarabine
Drug: allopurinol

First Posted Date: 2007-08-08

Last Posted Date: 2017-05-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00513474

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy